Diligence memo · auto-generated · as of July 2, 2026
Somite Therapeutics, Inc.
Somite Therapeutics, Inc. looks fair against its niche peers and is active on financing cadence.
Businessfiled
Somite Therapeutics, Inc. operates in Pharma, based in BOSTON.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Somite Therapeutics, Inc. has raised $47M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $47M on 2025-04-11.
Most recent recorded round closed around 2025-04-11.
Valuation (modeled)modeled
Provath models Somite Therapeutics, Inc. at approximately $317M (range $154M–$433M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.05× the median modeled value of Series C Pharma companies in 2025–2027 (6 peers) — value vs value, same stage and era. Within the normal band (105% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 15 mo ago; this sector typically re-raises about every 16 months.
Raising on or ahead of the sector's normal rhythm.
Comparablesmixed
Capital scale ranks ahead of 85% of Pharma peers (310 compared).
Modeled value ranks above 81% of those peers.
Closest niche peers: Click Therapeutics, Inc., Allay Therapeutics, Inc., Indapta Therapeutics Inc., Pheast Therapeutics, Inc., Bryn Pharma, LLC.
Peoplefiled
3 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.